NCT05227196View on ClinicalTrials.gov

A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People

PHASE1CompletedINTERVENTIONAL
Enrollment

546

Participants

Timeline

Start Date

February 4, 2022

Primary Completion Date

June 28, 2023

Study Completion Date

August 8, 2023

Conditions
Healthy VolunteersType 2 Diabetes
Interventions
DRUG

Semaglutide D Dose 1

Tablet given orally

DRUG

Semaglutide D Dose 2

Tablet given orally

DRUG

Semaglutide D Dose 3

Tablet given orally

DRUG

Semaglutide Dose 4

Tablet given orally

DRUG

Semaglutide Dose 5

Tablet given orally

DRUG

Semaglutide Dose 6

Tablet given orally

Trial Locations (3)

66212

Altasciences Clinical Kansas, Inc., Overland Park

90630

Altasciences Clinical LA, Inc., Cypress

H3P 3P1

Altasciences Company Inc., Montreal

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT05227196 - A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People | Biotech Hunter | Biotech Hunter